Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Daniel Lynch
AddedFeb 13, 2024
UpdatedMay 31, 2026
Daniel Lynch

Daniel Lynch

Board Member, Blueprint Medicines

CrunchbaseLinkedInThe Org

Daniel Lynch's Career

Blueprint Medicines
Blueprint Medicines

Cambridge, MA, US

Board Member· Board
bluebird bio
bluebird bio

Cambridge, MA, US

Board Member· Board
eGenesis
eGenesis

Cambridge, MA, US

Board Member· Board
Nimbus Therapeutics
Nimbus Therapeutics

Cambridge, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Daniel Lynch's Career

Blueprint Medicines
Blueprint Medicines
Public$2.4B6412008Cambridge, MA, US
Board Member· Board

Leadership at Blueprint Medicines

George DemetriGeorge DemetriBoard Member
Daniella BeckmanDaniella BeckmanBoard Member
Mark GoldbergMark GoldbergBoard Member
Alexis BorisyAlexis BorisyCo-Founder
Brian DrukerBrian DrukerCo-Founder
Kate HavilandKate HavilandBoard Member
bluebird bio
bluebird bio
Public$3.4B3231992Cambridge, MA, US
Board Member· Board

Leadership at bluebird bio

John AgwunobiJohn AgwunobiBoard Member
Elisabeth LeidermanElisabeth LeidermanBoard Member
Nick LeschlyNick LeschlyBoard Member
Andrew ObenshainAndrew ObenshainCEO
Philippe LeboulchPhilippe LeboulchFounder
Mark VachonMark VachonBoard Member

Similar to bluebird bio

Solid BiosciencesSolid BiosciencesCambridge, MA, USGene Therapy, Therapiesest. 2013Solid BiosciencesCambridge, MA, US · est. 2013

Solid Biosciences Inc., a US-based biotech firm, develops therapies and devices for muscular dystrophy.

Public · $441.3M87
RegenxbioRegenxbioRockville, MD, USGene Therapyest. 2008RegenxbioRockville, MD, US · est. 2008

REGENXBIO Inc., a global biotech firm, specializes in developing and commercializing gene therapy solutions.

Public · $638.2M401
BiogenBiogenCambridge, MA, USPharmaceuticals, Therapiesest. 1978BiogenCambridge, MA, US · est. 1978

Global biotech leader in neurology, oncology, and immunology therapies for various diseases.

Public · $1.5B8.7k
Generation BioGeneration BioCambridge, MA, USGenetic Medicinesest. 2016Generation BioCambridge, MA, US · est. 2016

Generation Bio Co.: A US-based biotech firm specializing in genetic medicines for systemic and hepatic diseases.

Public · $536.4M150
eGenesis
eGenesis
Series C$265M1052015Cambridge, MA, US
Board Member· Board

Leadership at eGenesis

Isaac CiechanoverIsaac CiechanoverBoard Member
Bob MoreBob MoreBoard Member
Al WiegmanAl WiegmanBoard Member
Boris NikolicBoris NikolicBoard Member
Julie SunderlandJulie SunderlandBoard Member
Mike CurtisMike CurtisCEO

Similar to eGenesis

Mammoth BiosciencesMammoth BiosciencesSan Francisco, CA, USCrispr Productsest. 2017Mammoth BiosciencesSan Francisco, CA, US · est. 2017

Mammoth Biosciences: An American biotech firm innovating CRISPR products to improve lives.

Series D · $264.5M195
InGeneronInGeneronHouston, TX, USRegenerative Therapiesest. 2006InGeneronHouston, TX, US · est. 2006

InGeneron: A multinational biotech firm unlocking patient healing through innovative regenerative therapies.

Series D · $51M32
ExogenesisExogenesisBillerica, MA, USMedical Devicesest. 2005ExogenesisBillerica, MA, US · est. 2005

Exogenesis Corp., based in Billerica, US, develops and processes implantable medical devices.

Seed · $7.8M17
InscriptaInscriptaBoulder, CO, USGenome Engineeringest. 2015InscriptaBoulder, CO, US · est. 2015

Inscripta: Pioneering scalable digital genome engineering with an advanced, fully automated CRISPR-based platform.

Series A · $463.9M178
Nimbus Therapeutics
Nimbus Therapeutics
Public$637M1122009Cambridge, MA, US
Board Member· Board

Leadership at Nimbus Therapeutics

Vicki SatoVicki SatoBoard Member
Laura StoppelLaura StoppelBoard Member
Anne McGeorgeAnne McGeorgeBoard Member
Bruce BoothBruce BoothBoard Member
Steve HallSteve HallBoard Member
Ramy FaridRamy FaridBoard Member

Similar to Nimbus Therapeutics

NGM BiopharmaceuticalsNGM BiopharmaceuticalsSouth San Francisco, CA, USTherapeuticsest. 2007NGM BiopharmaceuticalsSouth San Francisco, CA, US · est. 2007

NGM Biopharmaceuticals: A clinical-stage company developing novel therapeutics for various diseases in the US.

Public · $420.4M225
Nirogy TherapeuticsNirogy TherapeuticsNatick, MA, USDrug Developmentest. 2013Nirogy TherapeuticsNatick, MA, US · est. 2013

Nirogy Therapeutics: Innovating small molecule drugs to target cellular transporters and disrupt tumor growth.

Series A · $18.5M16
Microbiome TherapeuticsMicrobiome TherapeuticsBroomfield, CO, USMedical Researchest. 2009Microbiome TherapeuticsBroomfield, CO, US · est. 2009

Microbiome Therapeutics LLC: A US-based medical research firm specializing in metabolic disease solutions.

Series B · $3M30
Renibus TherapeuticsRenibus TherapeuticsSouthlake, TX, USBiotechest. 2016Renibus TherapeuticsSouthlake, TX, US · est. 2016

Rénibus Therapeutics: A biotech leader in preventing, treating, and diagnosing kidney disease.

Series B · $214.7M200

Daniel Lynch's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Daniel Lynch

Michael KlichinskyMichael KlichinskyCo-Founder · Carisma TherapeuticsSanford ZweifachSanford ZweifachBoard Member · Carisma TherapeuticsSaar GillSaar GillCo-Founder · Carisma TherapeuticsBjörn OdlanderBjörn OdlanderBoard Member · Carisma TherapeuticsCourt R. TurnerCourt R. TurnerBoard Member · AfraxisAmy SchulmanAmy SchulmanBoard Member · Alnylam Pharmaceuticals aln